Avana 50 mg contains avanafil, a medicine used for erectile dysfunction (ED). It is one of the dose strengths of avanafil introduced after the drug was approved for medical use.

The first official introduction (regulatory approval) of avanafil in general occurred when the U.S. Food and Drug Administration (FDA) approved it on April 27, 2012 for the treatment of erectile dysfunction. This approval marked the first time avanafil became available as a prescription medication in the United States.

After FDA approval, avanafil was launched in different strengths, including Avana 50 mg, 100 mg, and 200 mg tablets, as part of its commercial rollout under the brand name Stendra. The 50 mg strength was introduced as a lower starting or adjusted dose option, especially for patients who may need reduced dosage due to tolerance, side effects, or interactions with other medicines.

In Europe and other regions, avanafil (marketed as Spedra) was approved later, around 2013, expanding its availability globally.

In summary, Avana 50 mg is part of the original avanafil launch, which began after FDA approval in April 2012, with the 50 mg dose introduced as one of the standard clinical dosing options for safer and flexible treatment of ED.